Thailand’s HIV crisis is back after health chiefs revealed more than half a million people in the kingdom are living with the ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Winning Founding Managing Editor and Executive Director of Cns (Citizen News Service) and Is a Feminist, Health and Development Justice Advocate.Scientific research has gifted us with a range of ...

As U.S. HIV/AIDS aid wanes, Thailand thrives with local leadership and community care — offering a model for others amid a global funding crisis.

"To end AIDS as a public health emergency we need a far stronger focus on prevention, and not just on keeping people living with HIV alive and well. New infections are like a leaking tap - "every drop ...

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be ...

Results from studies have shown the overwhelming efficacy of twice-yearly injections of Lenacapavir (LEN) in the prevention of HIV infections compared to standard oral preventive HIV medicines ...

The Centers for Disease Control and Prevention estimated in May that between 2018 and 2022, annual U.S. HIV transmissions declined by a modest 12%, from 36,200 to 31,800 cases.

Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections. FDA approves new twice-yearly HIV shot. What to know ...